Perform Another (Advanced) Search

1.  News: ARISE Trials Shows Promising Results for Diabetes (Clinical Trials Today)
...description: Atherogenics reported positive results from a phase III trial of succinobucol (AGI-1067), an antioxidant oral vascular cell adhesion molecule-1 (VCAM-1) gene expression inhibitor, for the treatment of ...
View Page

2.  CenterWatch Clinical Industry Provider Profile(4157), SpectraCell Laboratories, Houston, TX
...individual's white blood cells respond to varied environments of vitamins, minerals, amino acids and antioxidants. By evaluating the functionality of specific nutrients in a patient's own cells, individual differences ...
...Carnitine • Glutamine • Serine • Lipoic Acid • Oleic Acid • Choline • Inositol • Fructose Intolerance • Glucose/ Insulin Metabolism • TOTAL Antioxidant Function Contact Info Nichole Herms Marketing SpectraCell Laboratories 10401 Town Park Drive Houston, TX 77072 ...
View Page

3.  Study Posting (799) Trial #163139, Amyotrophic Lateral Sclerosis (ALS), Boston, MA
...Ceftriaxone has been demonstrated to upregulate the expression of glutamate transporters in brain and has antioxidant properties. Ceftriaxone prolongs survival of a transgenic mouse model of ALS [1]. Preclinical evidence suggests ...
View Page

4.  Study Posting (799) Trial #163131, Amyotrophic Lateral Sclerosis (ALS), Boston, MA
...Ceftriaxone has been demonstrated to upregulate the expression of glutamate transporters in brain and has antioxidant properties. Ceftriaxone prolongs survival of a transgenic mouse model of ALS [1]. Preclinical evidence suggests ...
View Page

5.  Study Posting (799) Trial #156966, Amyotrophic Lateral Sclerosis (ALS), Boston, MA
...Ceftriaxone has been demonstrated to upregulate the expression of glutamate transporters in brain and has antioxidant properties. Ceftriaxone prolongs survival of a transgenic mouse model of ALS [1]. Preclinical evidence suggests ...
View Page

6.  Study Posting (799) Trial #156976, *Healthy Patient Studies, Boston, MA
...Ceftriaxone has been demonstrated to upregulate the expression of glutamate transporters in brain and has antioxidant properties. Ceftriaxone prolongs survival of a transgenic mouse model of ALS [1]. Preclinical evidence suggests ...
View Page

7.  Newly Approved Drug Therapies (386) Lustra, Medicis Pharmaceutical,
...Mechanism of Action Lustra contains 4% hydroquinone in a vehicle containing glycolic acid and an antioxidant complex. Jobson Medical Information • Privacy | • Glossary Copyright © 1995-2010 Jobson Medical Information LLC. Designed by ...
View Page

8.  Study Posting (2246) Trial #63467, Post Menopause, Duarte, CA
...to last approximately four months. Grape seed extract is sold at many stores as an antioxidant. Research studies have shown that grape seed extract may have a beneficial effect on cardiovascular ...
View Page

9.  Study Posting (5339) Trial #157736, Parkinson's Disease, Bronx, NY
...Need for symptomatic treatment with dopaminergic therapy (Sinemet or dopamine agonists or amantadine) -Use of antioxidants • Use of neuroleptics Dr. Cathy Chuang, Assistant Professor Einstein-Montefiore Institute for Clinical & Translational Research ...
View Page

10.  Study Posting (709) Trial #48962, High Cholesterol (Hyperlipidemia), Palo Alto, CA
...time-points during the study. Participants will receive a personal assessment of blood cholesterol levels, antioxidant status, clotting factors, blood pressure and nutritional analysis of their diets during the study. All ...
View Page

11.  Study Posting (3356) Trial #162666, Diabetic Neuropathy, Chicago, IL
...Use pf gamma-linolenic acid (GLA), alpha-lipoic acid (or any other high dose dietary antioxidant supplement) • Uncontrolled hypertension (>200mmHg/110 mmHg) • New malignant neoplasm (except basal or squamous cell carcinoma ...
View Page

12.  CenterWatch: New Medical Therapies in Disease Category (103), Musculoskeletal Diseases
...2005 Aeolus Pharmaceuticals reported interim results from a phase I trial investigating AEOL 10150 , a antioxidant neuroprotectant under development for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's ...
View Page

13.  CenterWatch: New Medical Therapies in Disease Category (278), Neurologic Disorders
...2005 Aeolus Pharmaceuticals reported interim results from a phase I trial investigating AEOL 10150 , a antioxidant neuroprotectant under development for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's ...
View Page

14.  CenterWatch: New Medical Therapies in Disease Category (160), Amyotrophic Lateral Sclerosis (ALS)
...2005 Aeolus Pharmaceuticals reported interim results from a phase I trial investigating AEOL 10150 , a antioxidant neuroprotectant under development for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's ...
View Page

15.  CenterWatch: New Medical Therapies in Disease Category (302), Vascular Diseases
...dependent increases in blood levels of AC3056, as well as dose-dependent increases in serum antioxidant activity. The drug was well tolerated with no safety concerns. AC3056 is being developed by ...
View Page

16.  CenterWatch: New Medical Therapies in Disease Category (17), Atherosclerosis
...dependent increases in blood levels of AC3056, as well as dose-dependent increases in serum antioxidant activity. The drug was well tolerated with no safety concerns. AC3056 is being developed by ...
View Page